Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Danish leader will face a challenging landscape among competitors ...

Law Offices of Howard G. Smith continues its investigation on behalf of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) investors concerning the Company's possible violations of federal ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

The Law Offices of Frank R. Cruz continues its investigation of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) on behalf of investors concerning the Company's possible violations of ...